{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:43:24Z","timestamp":1782301404802,"version":"3.54.5"},"reference-count":62,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.drudis.2020.04.014","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T12:45:56Z","timestamp":1588164356000},"page":"1239-1244","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-901X","authenticated-orcid":false,"given":"Daniele","family":"Bani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2020.04.014_bib0005","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(09)60622-X","article-title":"Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel- group, dose-finding phase IIb study","volume":"373","author":"Teerlink","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2020.04.014_bib0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(12)61855-8","article-title":"Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial","volume":"381","author":"Teerlink","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2020.04.014_bib0015","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1681\/ASN.2019060597","article-title":"AT1R-AT2R-RXFP1 functional crosstalk in myofibroblasts: impact on the therapeutic targeting of renal and cardiac fibrosis","volume":"30","author":"Chow","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0020","series-title":"Reasanz","author":"EMA","year":"2014"},{"key":"10.1016\/j.drudis.2020.04.014_bib0025","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"RELAX-AHF-2 Committees Investigators. Effects of serelaxin in patients with acute heart failure","volume":"381","author":"Metra","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2020.04.014_bib0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/ejhf.1692","article-title":"Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis","volume":"22","author":"Teerlink","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.drudis.2020.04.014_bib0035","article-title":"From pregnancy to cardiovascular disease: lessons from relaxin-deficient animals to understand relaxin actions in the vascular system","volume":"26","author":"Sherwood","year":"2019","journal-title":"Microcirculation"},{"key":"10.1016\/j.drudis.2020.04.014_bib0040","first-page":"585","article-title":"Relaxin in human pregnancy serum measured with an homologous radioimmunoassay","volume":"69","author":"Bell","year":"1987","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/cmt.4.2.137.143","article-title":"Relaxin: a possible future preventive therapy for cardiovascular disease in postmenopausal women and men?","volume":"4","author":"Bigazzi","year":"2001","journal-title":"Climacteric"},{"key":"10.1016\/j.drudis.2020.04.014_bib0050","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1126\/science.1065654","article-title":"Activation of orphan receptors by the hormone relaxin","volume":"295","author":"Hsu","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.drudis.2020.04.014_bib0055","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1096\/fj.13-233429","article-title":"Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment","volume":"28","author":"Jelinic","year":"2014","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2020.04.014_bib0060","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/0140-6736(92)90665-P","article-title":"Cardiac effects of relaxin in rats","volume":"339","author":"Kakouris","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2020.04.014_bib0065","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/0029-7844(95)00493-9","article-title":"Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model","volume":"87","author":"Coulson","year":"1996","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0070","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1210\/jcem-70-6-1771","article-title":"Relaxin in the peri-implantation period","volume":"70","author":"Stewart","year":"1990","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.drudis.2020.04.014_bib0075","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1073\/pnas.89.6.2384","article-title":"Relaxin binding in the rat heart atrium","volume":"89","author":"Osheroff","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2020.04.014_bib0080","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/sj.bjp.0704922","article-title":"Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin","volume":"137","author":"Kompa","year":"2002","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0085","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/CIRCRESAHA.113.301646","article-title":"Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts","volume":"113","author":"Parikh","year":"2013","journal-title":"Circ. Res."},{"key":"10.1016\/j.drudis.2020.04.014_bib0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1582-4934.2011.01328.x","article-title":"Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro: clues for cardiac regeneration","volume":"16","author":"Nistri","year":"2012","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.drudis.2020.04.014_bib0095","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12020-018-1534-3","article-title":"Relaxin activates AMPK- AKT signaling and increases glucose uptake by cultured cardiomyocytes","volume":"60","author":"Arag\u00f3n-Herrera","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.drudis.2020.04.014_bib0100","doi-asserted-by":"crossref","first-page":"H29","DOI":"10.1152\/ajpheart.00482.2008","article-title":"Relaxin alters cardiac myofilament function through a PKC-dependent pathway","volume":"297","author":"Shaw","year":"2009","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1096\/fj.14-254854","article-title":"Relaxin protects cardiac muscle cells from hypoxia\/reoxygenation injury: involvement of the Notch-1 pathway","volume":"29","author":"Boccalini","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2020.04.014_bib0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/1479-5876-11-251","article-title":"Notch signaling activation contributes to cardioprotection provided by ischemic preconditioning and postconditioning","volume":"11","author":"Zhou","year":"2013","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drudis.2020.04.014_bib0115","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1210\/en.2004-0209","article-title":"Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo","volume":"145","author":"Samuel","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.drudis.2020.04.014_bib0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063896","article-title":"Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-\u03b2\/Smad3 signaling","volume":"8","author":"Sassoli","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2020.04.014_bib0125","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1111\/j.1582-4934.2008.00503.x","article-title":"Functional and histopathological improvement of the post-infarcted rat heart upon myoblast cell grafting and relaxin therapy","volume":"13","author":"Bonacchi","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.drudis.2020.04.014_bib0130","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/labinvest.2010.198","article-title":"Relaxin remodels fibrotic healing following myocardial infarction","volume":"91","author":"Samuel","year":"2011","journal-title":"Lab. Invest."},{"key":"10.1016\/j.drudis.2020.04.014_bib0135","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bph.13523","article-title":"The actions of relaxin on the human cardiovascular system","volume":"174","author":"Sarwar","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0140","first-page":"337","article-title":"Effects of relaxin on the microvasculature of mouse mammary gland","volume":"3","author":"Bani","year":"1988","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0145","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0306-3623(96)00171-1","article-title":"Relaxin: a pleiotropic hormone","volume":"28","author":"Bani","year":"1997","journal-title":"Gen. Pharmacol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/VHRM.S2177","article-title":"Relaxin as a natural agent for vascular health","volume":"4","author":"Bani","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.drudis.2020.04.014_bib0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2009.198","article-title":"Cardiovascular effects of relaxin: from basic science to clinical therapy","volume":"7","author":"Du","year":"2010","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0160","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/bph.13614","article-title":"Vascular actions of relaxin: nitric oxide and beyond","volume":"174","author":"Leo","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0165","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/sj.ki.5000264","article-title":"Relaxin in cardiovascular and renal disease","volume":"69","author":"Samuel","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.drudis.2020.04.014_bib0170","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1161\/HYPERTENSIONAHA.109.149369","article-title":"Relaxin therapy reverses large artery remodeling and improves arterial compliance in senescent spontaneously hypertensive rats","volume":"55","author":"Xu","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2020.04.014_bib0175","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1476-5381.1995.tb16377.x","article-title":"Relaxin-induced increased coronary flow through stimulation of nitric oxide production","volume":"116","author":"Bani-Sacchi","year":"1995","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0180","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1124\/jpet.104.080655","article-title":"Multiple binding sites revealed by interaction of relaxin family peptides with native and chimeric relaxin family peptide receptors 1 and 2 (LGR7 and LGR8)","volume":"313","author":"Halls","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2020.04.014_bib0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.regpep.2007.05.004","article-title":"A novel, simple bioactivity assay for relaxin based on inhibition of platelet aggregation","volume":"144","author":"Bani","year":"2007","journal-title":"Regul. Pept."},{"key":"10.1016\/j.drudis.2020.04.014_bib0190","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/humrep\/14.3.800","article-title":"Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women","volume":"14","author":"Unemori","year":"1999","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.drudis.2020.04.014_bib0195","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1524-475X.2000.00361.x","article-title":"Relaxin induces vascular endothelial growth factor expression and angiogenesis selectively at wound sites","volume":"8","author":"Unemori","year":"2000","journal-title":"Wound Repair Regen."},{"key":"10.1016\/j.drudis.2020.04.014_bib0200","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1007\/s00018-003-2169-x","article-title":"Relaxin: a pregnancy hormone as central player of body fluid and circulation homeostasis","volume":"60","author":"Dschietzig","year":"2003","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.drudis.2020.04.014_bib0205","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/187152507780363179","article-title":"Relaxin as a cardiovascular hormone: physiology, pathophysiology and therapeutic promises","volume":"5","author":"Nistri","year":"2007","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"10.1016\/j.drudis.2020.04.014_bib0210","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2018.12.016","article-title":"Cardioprotective actions of relaxin","volume":"487","author":"Martin","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0215","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/bph.13695","article-title":"Serelaxin in clinical development: past, present and future","volume":"174","author":"Unemori","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0220","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/eurheartj\/eht459","article-title":"A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure","volume":"35","author":"Ponikowski","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2020.04.014_bib0225","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1096\/fasebj.5.7.2010056","article-title":"Role of endothelial dysfunction in the pathogenesis of reperfusion injury after myocardial ischemia","volume":"5","author":"Lefer","year":"1991","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2020.04.014_bib0230","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1089\/ars.2007.1636","article-title":"Role of oxygen in postischemic myocardial injury","volume":"9","author":"Kutala","year":"2007","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.drudis.2020.04.014_bib0235","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/01.RES.82.8.891","article-title":"Inhibition of rat cardiac muscle contraction and mitochondrial respiration by endogenous peroxynitrite formation during posthypoxic reoxygenation","volume":"82","author":"Xie","year":"1998","journal-title":"Circ. Res."},{"key":"10.1016\/j.drudis.2020.04.014_bib0240","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1210\/endo.138.11.5520","article-title":"Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts: evidence for an involvement of nitric oxide","volume":"138","author":"Masini","year":"1997","journal-title":"Endocrinology"},{"key":"10.1016\/j.drudis.2020.04.014_bib0245","first-page":"1367","article-title":"Relaxin protects against myocardial injury caused by ischemia and reperfusion in rat heart","volume":"152","author":"Bani","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0250","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1096\/fj.04-3664fje","article-title":"Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model","volume":"19","author":"Perna","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2020.04.014_bib0255","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.biopha.2016.09.054","article-title":"Effects of relaxin on cardiac fibrosis, apoptosis, and tachyarrhythmia in rats with myocardial infarction","volume":"84","author":"Wang","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drudis.2020.04.014_bib0260","first-page":"609","article-title":"Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia\/reperfusion injury via eNOS-dependent mechanism","volume":"113","author":"Valle Raleigh","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.drudis.2020.04.014_bib0265","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s00395-019-0739-9","article-title":"Relaxin mitigates microvascular damage and inflammation following cardiac ischemia-reperfusion","volume":"114","author":"Gao","year":"2019","journal-title":"Basic Res. Cardiol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0270","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.mce.2019.01.013","article-title":"Relaxin-2 for heart failure with preserved ejection fraction (HFpEF): Rationale for future clinical trials","volume":"487","author":"Dschietzig","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0275","doi-asserted-by":"crossref","first-page":"871","DOI":"10.7326\/0003-4819-132-11-200006060-00004","article-title":"Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial","volume":"132","author":"Seibold","year":"2000","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drudis.2020.04.014_bib0280","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1023\/A:1018901009062","article-title":"The pharmacokinetics of recombinant human relaxin in nonpregnant women after intravenous, intravaginal, and intracervical administration","volume":"10","author":"Chen","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.drudis.2020.04.014_bib0285","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1210\/en.2010-0286","article-title":"Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis","volume":"151","author":"Hewitson","year":"2010","journal-title":"Endocrinology"},{"key":"10.1016\/j.drudis.2020.04.014_bib0290","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1475-2867-13-59","article-title":"Role of relaxin-2 in human primary osteosarcoma","volume":"13","author":"Ma","year":"2013","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.drudis.2020.04.014_bib0295","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.mce.2018.12.008","article-title":"Relaxin in liver transplantation: a personal perspective","volume":"482","author":"Kageyama","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0300","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1039\/C5SC04754D","article-title":"A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1","volume":"7","author":"Hossain","year":"2016","journal-title":"Chem. Sci."},{"key":"10.1016\/j.drudis.2020.04.014_bib0305","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/bph.13656","article-title":"Synthetic non-peptide low molecular weight agonists of the relaxin receptor 1","volume":"174","author":"Agoulnik","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2020.04.014_bib0310","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pharmthera.2018.02.008","article-title":"The relaxin receptor as a therapeutic target \u2014 perspectives from evolution and drug targeting","volume":"187","author":"Bathgate","year":"2018","journal-title":"Pharmacol. Ther."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620301628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644620301628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:44:16Z","timestamp":1761223456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644620301628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":62,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1359644620301628"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2020.04.014","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2020.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}